Literature DB >> 22665369

Nuclear localization signal in a cancer-related transcriptional regulator protein NAC1.

Kosuke Okazaki1, Naomi Nakayama, Yuko Nariai, Kentaro Nakayama, Kohji Miyazaki, Riruke Maruyama, Hiroaki Kato, Shunichi Kosugi, Takeshi Urano, Gyosuke Sakashita.   

Abstract

Nucleus accumbens-associated protein 1 (NAC1) might have potential oncogenic properties and participate in regulatory networks for pluripotency. Although NAC1 is described as a transcriptional regulator, the nuclear import machinery of NAC1 remains unclear. We found, using a point mutant, that dimer formation was not committed to the nuclear localization of NAC1 and, using deletion mutants, that the amino-terminal half of NAC1 harbored a potential nuclear localization signal (NLS). Wild type, but not mutants of this region, alone was sufficient to drive the importation of green fluorescent protein (GFP) into the nucleus. Bimax1, a synthetic peptide that blocks the importin α/β pathway, impaired nuclear localization of NAC1 in cells. We also used the binding properties of importin to demonstrate that this region is an NLS. Furthermore, the transcriptional regulator function of NAC1 was dependent on its nuclear localization activity in cells. Taken together, these results show that the region with a bipartite motif constitutes a functional nuclear import sequence in NAC1 that is independent of NAC1 dimer formation. The identification of an NAC1 NLS thus clarifies the mechanism through which NAC1 translocates to the nucleus to regulate the transcription of genes involved in oncogenicity and pluripotency.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665369     DOI: 10.1093/carcin/bgs193

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  8 in total

1.  Identification of the NAC1-regulated genes in ovarian cancer.

Authors:  Min Gao; Ren-Chin Wu; Alice L Herlinger; Kailee Yap; Jung-Won Kim; Tian-Li Wang; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2013-11-06       Impact factor: 4.307

2.  The effect of dexamethasone on lentiviral vector infection is associated with importin α

Authors:  Shengchang Deng; Ying Zhou; Dong Ouyang; Junping Xiong; Lei Zhang; Changchun Tu; Keping Zhang; Zengliang Song; Fanglin Zhang
Journal:  Biomed Rep       Date:  2013-11-01

3.  NAC1 Regulates Somatic Cell Reprogramming by Controlling Zeb1 and E-cadherin Expression.

Authors:  Francesco Faiola; Nuoya Yin; Miguel Fidalgo; Xin Huang; Arven Saunders; Junjun Ding; Diana Guallar; Baoyen Dang; Jianlong Wang
Journal:  Stem Cell Reports       Date:  2017-08-03       Impact factor: 7.765

4.  Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells.

Authors:  Tongfa Ju; Huicheng Jin; Rongchao Ying; Qi Xie; Chunhua Zhou; Daquan Gao
Journal:  Mol Med Rep       Date:  2017-07-14       Impact factor: 2.952

5.  G196 epitope tag system: a novel monoclonal antibody, G196, recognizes the small, soluble peptide DLVPR with high affinity.

Authors:  Kasumi Tatsumi; Gyosuke Sakashita; Yuko Nariai; Kosuke Okazaki; Hiroaki Kato; Eiji Obayashi; Hisashi Yoshida; Kanako Sugiyama; Sam-Yong Park; Joji Sekine; Takeshi Urano
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

6.  Cancer-related transcription regulator protein NAC1 forms a protein complex with CARM1 for ovarian cancer progression.

Authors:  Naomi Nakayama; Gyosuke Sakashita; Yuko Nariai; Hiroaki Kato; Kaori Sinmyozu; Jun-Ichi Nakayama; Satoru Kyo; Takeshi Urano; Kentaro Nakayama
Journal:  Oncotarget       Date:  2018-06-19

7.  Effect of taxol on the expression of FoxM1 ovarian cancer-associated gene.

Authors:  Zeng Liu; Y U Xiao; Siqing Ning; Zhao Yuan Li; Yuanyuan Zhu; Gang Hu
Journal:  Oncol Lett       Date:  2016-04-22       Impact factor: 2.967

8.  NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells.

Authors:  Kohei Morita; Tomomi Fujii; Hiroe Itami; Tomoko Uchiyama; Tokiko Nakai; Kinta Hatakeyama; Aya Sugimoto; Makito Miyake; Yasushi Nakai; Nobumichi Tanaka; Keiji Shimada; Masaharu Yamazaki; Kiyohide Fujimoto; Chiho Ohbayashi
Journal:  Cancers (Basel)       Date:  2018-09-21       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.